ArticleFrontiers in pharmacology2022
Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world.Cardiovascular drugs and therapy · 2026Article
- Article
- Tiopronin safety in cystinuria: first real-world pharmacovigilance analysis using the FDA Adverse Event Reporting System (FAERS): an EAU YAU and Endourology sections review.Pediatric nephrology (Berlin, Germany) · 2026Article
- Anthracycline Cardiotoxicity: A Real-World Study Based on FDA Adverse Event Reporting System Database.Cardiovascular therapeutics · 2026Article
- QT-related adverse events with ondansetron and olanzapine: a real-world FAERS analysis with implications for oncology anti-emetic practice.Frontiers in pharmacology · 2026Article
- Bridging pharmacovigilance and genetic insight: investigating drugs and indications for breast cancer risk in women with autoimmune diseases.Journal of translational medicine · 2025Article
- Postmarketing safety evaluation of pemetrexed using FAERS and JADER databases.Scientific reports · 2025Article
- A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database.Scientific reports · 2025Article
- Adverse events of ursodeoxycholic acid: a real-world pharmacovigilance study using FAERS (2004-2023).Frontiers in medicine · 2025Article
- Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database.Scientific reports · 2024Article
- Safety assessment of Tafamidis: a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.BMC pharmacology & toxicology · 2024Article
- Drug-induced coagulopathies: a real-world pharmacovigilance study using the FDA adverse event reporting system.Frontiers in pharmacology · 2024Article
- The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.PloS one · 2024Article
- Cardiovascular adverse events associated with antibody-drug conjugates (ADCs): a pharmacovigilance study based on the FAERS database.Frontiers in pharmacology · 2024Article
- A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.Frontiers in pharmacology · 2024Article
- Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).Frontiers in pharmacology · 2023Article
- A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database.Frontiers in pharmacology · 2023Article
- A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.